metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-61 LIVER TRANSPLANTATION IN HEPATOCARCINOMA: SURVIVAL AND RECURRENCE IN TRANSP...
Journal Information
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Share
Share
Download PDF
More article options
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Open Access
P-61 LIVER TRANSPLANTATION IN HEPATOCARCINOMA: SURVIVAL AND RECURRENCE IN TRANSPLANTED PATIENTS WITH HEPATOCARCINOMA
Visits
469
Daniela García, Fodda Chelech, Andrea Jiménez, Alvaro Urzúa, Maximo Cattaneo, Juan Pablo Roblero, Alexis Iracheta, Jaime Poniachik
Sección de Gastroenterología, Departamento de Medicina Interna, Hospital Clínico Universidad de Chile, Santiago, Chile
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 24. Issue S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

More info
Introduction

Hepatocellular carcinoma (HCC) is the most common malignant liver tumor. Liver transplantation (LT) is considered potentially curative, achieving a survival of 70% at 5 years and a tumor recurrence <15% when the Milan criteria are used.

Objectives

To study the frequency of tumor recurrence in transplant patients with HCC and to evaluate survival at 1 and 5 years.

Methods

Retrospective study of 79 transplant patients with HCC, with a median of 62 years, 69% male. Clinical characteristics, pre LT and post LT Milan criteria, post LT tumor recurrence, and 1 and 5 year survival were analyzed. Statistical analysis with Kaplan Meier.

Results

The etiology of cirrhosis was 35% NASH, 15% OH, 12% HCV, with an average MELD of 17%, Child A 17%, B 45% and C 38%. 92% met the pre-LT Milan criteria and 63% according to the findings of the explant, of the latter, 16% (8/50) presented microvascular invasion. Overall survival at 1 and 5 years was 96% and 75%, respectively. HCC recurrence occurred in 10% (8/79), 7/8 outside Milan in the explant, with an average recurrence of 8 months and a surplus of 18 months.

Conclusion

HCC recurrence in this study was within the values ​​described in the literature, as well as short and long term survival. LT is an excellent treatment for the management of patients with HCC, achieving good survival results when they are within the Milan criteria.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos